The study on cyproterone acetate (Androcur and generics) is available - Ameli.fr

The demonstration of the links between taking cyproterone acetate (Androcur and generics) and the presence of meningioma has been subject to a publication by the National Health Insurance Fund (CNAM), with clinical experts and the National Agency for the Safety of Medicines and Health Products (ANSM).

This study has established that cyproterone acetate promotes the development of meningiom. The prolonged use of cyproterone acetate beyond 6 months, at an average dose, greater than or equal to 25 mg/d, multiplies the risk of meningioma by 7, and by 20 beyond a cumulative dose of 60 g, or 50 mg/d for 5 years, or 25 mg/d for 10 years.

Cyproterone acetate prescribers (Androcur and generics) and patients concerned received information recalling the recommendations for prescribing and monitoring these treatments.

This study is available on the “Statistics and publications” space of the Ameli site .

The study on cyproterone acetate (Androcur and generics) is available - Ameli.fr

Find the other Amavea articles here